60 Degrees Pharmaceuticals LLC   Report issue

Contributed to NME For profit Phase 2
Founded: Washington D.C. United States (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2017
NCT02569827
First Marketed Drug
2018
tafenoquine succinate (arakoda)
First NDA Approval
2018
tafenoquine succinate (arakoda)
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

60 Degrees Pharmaceuticals LLC | 60 DEGREES PHARMS

Active Ingredients

Marketed Drugs (1)

tafenoquine succinate (arakoda) (2018 NDA)

Drugs in Phase 2 Trials (3)

mdl 28574 (1 trial)

modipafant (1 trial)

tafenoquine succinate (arakoda) (2 trials)

Indications

Approved Indications


 

Malaria

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dengue (Phase 2)

Fever (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 3